Foresee Pharmaceuticals Announces Groundbreaking Phase 1 Results
Foresee Pharmaceuticals (TPEx: 6576) is excited to share notable updates regarding its Phase 1 clinical trial of linvemastat (FP-020), a distinctive and selective oral MMP-12 inhibitor. The trial, focused on assessing safety, tolerability, and pharmacokinetics, has been successfully completed and has revealed promising insights into the compound's potential.
Details of the Phase 1 Study
This clinical study was structured into two segments: the single ascending dose (SAD) and multiple ascending dose (MAD) evaluations. In the SAD segment, 40 healthy subjects were randomized to receive either a singular dose of linvemastat or a placebo. Subsequently, the MAD segment involved 24 participants who were given a daily dose of linvemastat over ten consecutive days. The well-structured design of this trial aimed to comprehensively assess the drug’s early-stage effects.
Safety Profile and Tolerability
According to Dr. Yisheng Lee, Chief Medical Officer of Foresee, the safety outcomes from the study highlight linvemastat's potential, as it demonstrated a favorable safety profile with no serious adverse events observed. While mild nausea and headache were recorded among treatment emergent adverse events (TEAEs), these symptoms subsided quickly, showcasing the drug's tolerability.
Implications for Future Trials
Dr. Wenjin Yang, the Chief Scientific Officer, expressed enthusiasm over the initial results, noting that linvemastat could be considered a best-in-class candidate due to its superior pharmacokinetic properties. The promising data from this first-in-human study paves the way for subsequent clinical trials, where varying dosing intervals will be explored further.
Therapeutic Potential of Linvemastat
Linvemastat emerges as a potential therapeutic option targeting severe asthma, chronic obstructive pulmonary disease (COPD), and inflammatory bowel diseases (IBD), areas that hold significant unmet needs. Dr. Bassem Elmankabadi, Senior Vice President of Clinical Development, emphasized this potential, as MMP-12's role in immune modulation and fibrosis positions linvemastat as a candidate for meaningful patient outcomes in future Phase 2 studies expected to commence in the coming years.
Commitment to Innovative Treatments
The leadership at Foresee, including CEO Dr. Ben Chien, shared a commitment to developing innovative treatments for difficult diseases. The drug is poised to enter multibillion-dollar markets and stands as a notable pipeline-in-a-drug opportunity. Its encouraging safety, tolerability, and pharmacokinetic profile puts linvemastat at the forefront of Foresee's endeavors to enhance patient quality of life.
About Linvemastat (FP-020)
Linvemastat is a next-generation, selective oral MMP-12 inhibitor specifically designed to combat inflammatory and fibrotic diseases. This product has exhibited notable potency and selectivity, drawing comparisons to its predecessor, aderamastat (FP-025). Early animal studies have already pointed to its efficacy in respiratory diseases and IBD, supporting its progression into further clinical evaluations.
About Foresee Pharmaceuticals Co., Ltd.
Foresee is a prominent biopharmaceutical company with operations across Taiwan and the U.S., renowned for its innovative R&D projects targeting rare and severe diseases presenting high unmet needs. Its rich product pipeline includes therapies currently in various stages of development, including the approved CAMCEVI® for advanced prostate cancer.
Frequently Asked Questions
What is linvemastat (FP-020)?
Linvemastat (FP-020) is a selective oral MMP-12 inhibitor aimed at treating inflammatory and fibrotic diseases such as asthma and IBD.
What were the main outcomes of the Phase 1 trial?
The Phase 1 trial demonstrated a favorable safety profile for linvemastat, with mild and recoverable side effects reported among participants.
When does Foresee plan to initiate Phase 2 trials?
Foresee plans to start Phase 2 trials focusing on severe asthma and IBD in the coming years, aiming to explore linvemastat's therapeutic potential further.
How does linvemastat compare to earlier treatments?
Linvemastat is designed to be a next-generation treatment that offers superior potency and selectivity compared to earlier MMP-12 inhibitors such as aderamastat (FP-025).
What is Foresee's broader mission?
Foresee Pharmaceuticals is committed to pioneering innovative treatments for severe diseases while addressing significant unmet medical needs through its advanced R&D initiatives.
